Children's Medical Center Corporation

Celgene Corporation

Other

Compleat LLC

Children's Hospital Medical Center

Entremed, Inc.

Robert J D'Amato

Moses J Folkman

Jamshed H Shah

Ofra Benny-Ratsaby

Judah M Folkman

Shawn J Green

John W Madsen

Avner Adini

Glenn M Swartz

Anthony Treston

Glenn M Swartz, Jr

Kimberly A Hunsucker

John Rougas

Barry P Conner

Takeru Yoshimura

Nancy Klauber DeMore

Peter Herman

Taturo Udagawa

Victor Pribdula

Adonia E Papathanassiu

William E Fogler

Kashi Javaherian

Victor S Pribluda

Christian Becker

A vessel has an inner flap and an outer flap that fold across a base of the vessel to form a cover. The inner flap includes a dam tab along the outer edge of the inner flap. When the inner flap is folded down, the free edge of this tab contacts the wall of the vessel and bends upward forming a 'folded edge' dam. This folded edge dam can either be one segment or be made of two or more segments divided by one or more V-shaped cuts to allow each segment to fold down and fit together seamlessly. A restrictive channel is formed by the outer and inner flaps together with the 'folded edge' dam, which is present in-between the outer and inner flaps.

Vessel with folded dam

Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these peptide analogs and uses thereof.

Pro-angiogenic fragments of prominin-1 and uses thereof

Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.

MetAP-2 inhibitor polymersomes for therapeutic administration

The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.

Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.

Prominin-1 peptide fragments and uses thereof

Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these pep tide analogs and uses thereof.

The invention provides new and useful analogs of 4-amino-thalidomide. These analogs include S(&#x2212;)-4-amino-thalidomide and R(+)-4-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.

Synthesis of 4-amino-thalidomide enantiomers

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.

Methods for treating blood-born tumors with thalidomide

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

Methods and compositions for inhibition of angiogenesis

Growing community of inventors

Lexington, MA, United States of America

Robert J D'Amato